Abstract

HAS considers that the Moderna COVID-19 mRNA (nucleoside modified) Vaccine can be used in people 18 years of age and over, including in the elderly, due to its efficacy and satisfactory tolerance profile.

HAS notes, however, that at this point:

  • vaccine efficacy has not been evaluated in younger subjects (<18 years);
  • vaccine efficacy on viral transmission could not be assessed.

HAS reminds that:

At this stage, there is no need to systematically vaccinate people who have already developed a symptomatic form of Covid-19 unless they wish to do so following a decision shared with the doctor and within a minimum period of time. 3 months from the onset of symptoms.

However, the defined prioritization strategy does not exclude - on the basis of an assessment of the individual benefit / risk ratio on a case-by-case basis, vaccination of non-elderly but particularly vulnerable subpopulations [1] and exposed to COVID-19 (severe immune deficiencies, malignant hemopathies, renal insufficiency on dialysis, solid organ transplants, etc.).

The HAS also specifies the situations of pregnancy, breastfeeding and a history of allergy. This vaccine cannot be co-administered with other vaccines at this time.

In addition, the HAS insists on the need to maintain all barrier gestures and social distancing measures at this stage.

The objectives of the program and the prioritization strategy will likely evolve depending on the knowledge acquired on the effectiveness of vaccines on asymptomatic forms and on transmission.

Recommendation Europe France Moderna COVID-19 vaccine COVID-19